It’s a rallying cry Alderman Joe Kelly Levasseur said he’s heard over the past week from resident across the city and state, ...

Last year, GLP-1s dominated many employer conversations as demand surged and pressure mounted from employees clamoring for ...

As the Dec. 31 end to federal subsidies for federal health care nears, pressure is mounting on insurers, providers, and the ...

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP ...

There is a great health threat facing American consumers who are unknowingly taking counterfeit or copycat versions of GLP-1 drugs.

New IFF report probes GLP-1 trends IFF, a flavor, fragrance, and ingredient company, has released a new report highlighting how the rapidly growing market of GLP-1 medication users is reshaping the ...

Eli Lilly's oral GLP-1 drug orforglipron shows promise in weight loss, with significant results in a 72-week trial, aiming for 2025 global approval.

Healthcare stocks have been the sick man of the S&P 500 this year. They’re ready for a revival.Sure, 2025 has been unpleasant. The Health Care Select Sector SPDR exchange-traded fund has fallen 3.7% ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.